Jim Kastenmayer
General Counsel at ARRIVENT BIOPHARMA, INC.
Net worth: 114 778 $ as of 2024-04-29
Jim Kastenmayer active positions
Companies | Position | Start | End |
---|---|---|---|
ARRIVENT BIOPHARMA, INC. | General Counsel | 2023-08-31 | - |
Corporate Secretary | 2023-08-31 | - |
Career history of Jim Kastenmayer
Former positions of Jim Kastenmayer
Companies | Position | Start | End |
---|---|---|---|
SPYRE THERAPEUTICS, INC. | Chief Executive Officer | 2022-08-23 | 2022-11-28 |
General Counsel | 2021-07-14 | 2023-05-15 | |
President | 2022-08-23 | 2022-11-28 | |
Corporate Secretary | 2022-11-28 | 2023-05-15 | |
VIELA BIO, INC. | General Counsel | 2019-12-31 | 2021-02-28 |
Corporate Secretary | 2019-12-31 | 2021-02-28 | |
ASTRAZENECA PLC | General Counsel | 2012-04-30 | 2019-11-30 |
Medimmune, Inc. | Corporate Officer/Principal | - | - |
Training of Jim Kastenmayer
Georgetown University Law Center | Graduate Degree |
Michigan State University | Doctorate Degree |
University of Virginia | Undergraduate Degree |
Statistics
International
United States | 8 |
United Kingdom | 2 |
Operational
General Counsel | 4 |
Corporate Secretary | 3 |
Graduate Degree | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
ASTRAZENECA PLC | Health Technology |
SPYRE THERAPEUTICS, INC. | Health Technology |
ARRIVENT BIOPHARMA, INC. | Health Technology |
Private companies | 2 |
---|---|
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Medimmune, Inc. | Health Technology |
- Stock Market
- Insiders
- Jim Kastenmayer
- Experience